However, in CRC, clinical responses to anti-PD-1 or anti-PD-L1 antibodies are restricted primarily to tumors with mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H), which represent only a small subset of cases [26, 27]. Here, CD274 is linked to colorectal carcinoma.